myTomorrows Enrolls 275 Duchenne Patients in Pre-Approval Programs

myTomorrows has successfully referred over 600 patients with Duchenne muscular dystrophy to clinical trials and expanded access programs worldwide, using its AI-powered precision matching platform, announced in a press release. Of these, nearly 300 patients have been enrolled, demonstrating the platform's effectiveness in improving access to treatment for rare disease communities.

Duchenne muscular dystrophy is a rare genetic disorder that causes progressive muscle weakness, primarily affecting boys. Despite the urgent need for research participation, barriers to accessing clinical trials remain significant. myTomorrows' platform automates clinical trial matching with up to 98% accuracy, helping patients and physicians overcome logistical and administrative challenges.

The platform rapidly sources and analyzes data from global public trial registries, aligning patient profiles with complex eligibility criteria in minutes. This process eases the recruitment burden for sponsors and research sites, facilitating timely access to emerging therapies for Duchenne patients. Additionally, myTomorrows provides personal guidance through dedicated Patient Navigators, who conducted over 5,000 multilingual support calls in 2024 alone, assisting patients and families through treatment discovery and access.